Article
BCG failure leads to heightened risk of bladder cancer death
Chicago-Patients with carcinoma in situ or recurrent Ta, Tis, or T1 bladdercancer are at increased risk of dying of the disease within 5 years unlessthey achieve a complete response with bacille Calmette-Guérin therapy,say researchers from the Southwest Oncology Group.
Related Videos
Urologist discusses drug cost savings, price transparency
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Final Thoughts and Clinical Trials in NMIBC
Uptake of New Treatments in Urology Practice
Patient Communication and Treatment Adherence in NMIBC
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, highlights recent advances in kidney stone technology
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Resective Surgery and Minimally Invasive Procedures For BPH
Related Content
